Social Accounts Sprite

Understanding the Conclusions of Taxotere® Clinical Studies


After patients began to develop severe complications, researchers have performed many Taxotere® clinical studies to learn more about the side effects of the drug. Taxotere® is commonly recommended as a chemotherapy treatment for breast, head, neck, lung, stomach, and prostate cancers. Unfortunately, many patients have experienced severe side effects after taking the drug, including permanent hair loss. Patient complications have prompted several studies into the drug and its effects, as well as lawsuits against the manufacturer, Sanofi S.A. If you or a loved one has suffered a serious complication or side effect after being prescribed Taxotere® as part of a chemotherapy regimen, please contact a member of our expert legal team today to schedule a complimentary case evaluation.

A woman who has suffered permanent hair loss
Numerous clinical studies have found a connection between Taxotere® and permanent hair loss.

Taxotere® Side Effects

Alopecia, or permanent hair loss, is one of the most troubling complications for Taxotere® patients. Additionally, there have been reports of several other troubling side effects, including:

  • Low white blood cell count
  • Increased risk of infection
  • Numbness in the fingers and toes
  • Changes in the color of the fingernails or toenails
  • Complete nail loss

If you have been injured by a defective drug, Speak with an Attorney

Clinical Studies on the Effects of Taxotere®

After reports of serious complications associated with Taxotere® began to surface, several clinical studies were conducted to evaluate the safety and efficacy of the drug:

  • At the 2014 NCRI Cancer Conference, a study was presented that found as many as 15 percent of Taxotere® patients suffered from pervasive or permanent alopecia. The researchers concluded that health care providers should take these serious side effects into account before choosing to include Taxotere® as part of a patient’s chemotherapy regimen.
  • A July 2012 article published in Journal of Clinical Oncology found that newer chemotherapy medications, including Taxotere®, were associated with a higher risk of more severe complications, both during and after treatment. The study found that patients taking these drugs were 40 percent more likely to suffer a fatal complication, while 52 percent were more likely to suffer severe side effects, when compared to patients who were prescribed traditional chemotherapy medications.
  • In a May 2012 article published in the Annals of Oncology journal, researchers found that women who were treated for breast cancer with Taxotere® and suffered alopecia were unresponsive to hair regrowth therapies.
  • In 2010, the results of a study sponsored by Sanofi in the 1990s were published in The New England Journal of Medicine. The researchers found that almost 10 percent of women who used Taxotere® as part of their chemotherapy regimen suffered from permanent alopecia.
  • A 2009 article published in the Journal of American Academy of Dermatology found a significant increase in permanent alopecia among patients who were prescribed high chemotherapy doses of medications such as Taxotere®.

Schedule a Free Case Evaluation

If you or a loved one has suffered a serious complication such as permanent hair loss after being prescribed Taxotere® for chemotherapy, please contact us today to schedule a consultation. We understand the devastating effects these complications can have on your quality of life and a qualified Taxotere® attorney will work diligently to secure compensation.

Request Your Free Evaluation Today

X CLOSE

Request Your Free Evaluation Today

X CLOSE